{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"A TE-ADA evaluable participant is considered to be TE-ADA positive if the participant has at least one post baseline titer that is a 4-fold or greater increase in titer from baseline measurement (treatment-boosted). If baseline result is ADA Not Present, then the participant is TE ADA positive if there is at least one post baseline result of ADA Present with titer \\>= 20 (treatment-induced).","groups":[{"description":"Participants received intravenous infusions of ramucirumab 9 mg/kg, gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.","id":"OG000","title":"Ramucirumab + Gemcitabine + Docetaxel"},{"description":"Participants received intravenous infusions of gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.","id":"OG001","title":"Gemcitabine + Docetaxel"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized participants who received at least one dose of study drug and had at least one non-missing baseline, post baseline ADA value.","reportingStatus":"POSTED","timeFrame":"Baseline Up to 6.94 months","title":"Number of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADA)","type":"SECONDARY","unitOfMeasure":"Participants"}